By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eyetech Pharmaceuticals, Inc. 

666 Fifth Avenue, 35th Floor

New York  New York  10103  U.S.A.
Phone: 212-582-8376 Fax: 212 582-2645


Big Pharma


Cell Matrix Inc. (Acquired By CancerVax)  Opthalmic applications of antibodies to denatured collagen

Company News
OSI Pharmaceuticals, Inc. (OSIP) to Divest Eye-Disease Program 7/27/2007 10:58:19 AM
The Day In Review: OSI Pharmaceuticals, Inc. (OSIP) Gives Up On Macugen 11/7/2006 5:49:53 PM
Lux Biosciences Appoints To Board Of Directors David Guyer, SVLS Venture Partner And Former CEO Of Eyetech Pharmaceuticals, Inc. (EYET) 7/11/2006 12:55:45 PM
OSI Pharmaceuticals, Inc. (OSIP) To Host Conference Call To Discuss (OSI) Eyetech Pharmaceuticals, Inc. (EYET) Integration Strategy 11/16/2005 6:20:30 PM
OSI Pharmaceuticals, Inc. (OSIP) Completes Its Acquisition Of Eyetech Pharmaceuticals, Inc. (EYET) 11/14/2005 2:24:38 PM
OSI Pharmaceuticals, Inc. (OSIP) Updates Status Of Pending Acquisition Of Eyetech Pharmaceuticals, Inc. (EYET) 11/10/2005 1:27:37 PM
Eyetech Pharmaceuticals, Inc. (EYET) Merger Delayed Over Drug Concerns 11/10/2005 1:19:21 PM
Eyetech Pharmaceuticals, Inc. (EYET) Reports Third Quarter 2005 Financial Results 11/1/2005 11:20:39 AM
Eyetech Pharmaceuticals, Inc. (EYET) Announces Enrollment Of The First Patient In A Phase 3 Clinical Trial Of Macugen(R) (pegaptanib sodium injection) In Diabetic Macular Edema (DME) And Diabetic Retinopathy10/19/2005 5:13:22 PM
Eyetech Pharmaceuticals (EYET) Announces Co-Founder Marty Glick Steps Down From Board To Act As Consultant10/19/2005 5:13:14 PM